Interaction entre Arformotérol et Budésonide et formotérol
Arformotérol et Budésonide et formotérol : les deux notices de prescription signalent cette association dans les termes les plus forts, tels qu'une contre-indication, une mise en garde encadrée ou une consigne de l'éviter.
Ne pas associer sans l'avis d'un prescripteur. Les termes de la notice cités ci-dessous sont les plus forts qu'emploie la FDA.
Ce que disent les notices FDA
D'après la notice Budésonide et formotérol (Budesonide and Formoterol Fumarate Dihydrate) · version du 2026-04-24
Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose.
Excessive Use of Budesonide and Formoterol Fumarate Dihydrate and Use with Other Long-Acting Beta 2 -Agonists As with other inhaled drugs containing beta 2 -adrenergic agents, budesonide and formoterol fumarate dihydrate should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medications containing LABA,…
In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions.
Patients using budesonide and formoterol fumarate dihydrate should not use an additional LABA (e.g., salmeterol, formoterol fumarate, arformoterol tartrate) for any reason, including prevention of exercise-induced bronchospasm (EIB) or the treatment of asthma or COPD.
If paradoxical bronchospasm occurs following dosing with budesonide and formoterol fumarate dihydrate, it should be treated immediately with an inhaled, short-acting bronchodilator, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL should be discontinued immediately, and alternative therapy should be instituted.
D'après la notice Arformotérol (arformoterol tartrate) · version du 2026-01-21
Arformoterol tartrate inhalation solution is contraindicated in patients with a history of hypersensitivity to arformoterol, racemic formoterol or to any other components of this product.
Use of a LABA, including arformoterol tartrate inhalation solution, without an inhaled corticosteroid is contraindicated in patients with asthma.
Use of long-acting beta 2 -adrenergic agonists (LABA) as monotherapy [without inhaled corticosteroids (ICS)] for asthma is associated with an increased risk of asthma-related death.
Excessive Use of Arformoterol Tartrate Inhalation Solution and Use with Other Long-Acting Beta2-Agonists Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.
Paradoxical Bronchospasm As with other inhaled beta 2 -agonists, arformoterol tartrate inhalation solution can produce paradoxical bronchospasm that may be life-threatening.
Vous prenez autre chose que ces deux-là ? Les interactions se cumulent. Vérifiez toute votre liste en une fois ; elle reste dans votre navigateur.
Ouvrir dans le vérificateurCeci n'est pas un avis médical. Interaction Checker cite le texte des notices FDA et des fiches d'information du NIH. L'importance d'une interaction dans votre cas dépend des doses, des horaires de prise, de la fonction rénale et hépatique et d'autres problèmes de santé. Vérifiez auprès d'un pharmacien ou d'un prescripteur.